Viking Therapeutics Launches VK2735 Oral Trial for Obesity Management #USA #San_Diego #Viking_Therapeutics #VK2735 #obesity_management

Viking Therapeutics Launches VK2735 Oral Trial for Obesity Management #USA #San_Diego #Viking_Therapeutics #VK2735 #obesity_management
Viking Therapeutics Secures $575 Million from Major Stock and Note Offerings to Propel Growth #United_States #San_Diego #Clinical_Trials #Viking_Therapeutics #VK2735
Kuehn Law Investigates Breaches by Viking Therapeutics, Inc. Directors for Investors' Rights #United_States #New_York #Kuehn_Law #Viking_Therapeutics #Investors_Rights
Viking Therapeutics Successfully Upsizes Its $500 Million Offering of Common Stock and Convertible Senior Notes #United_States #San_Diego #Clinical_Trials #Viking_Therapeutics #VKTX
Viking Therapeutics Plans Major Stock and Note Offerings to Fund Obesity Treatment Development #USA #San_Diego #Viking_Therapeutics #Biopharmaceutical #VK2735
Viking Therapeutics Unveils Promising Results from VK2735 Weight Maintenance Study #United_States #San_Diego #Viking_Therapeutics #obesity #VK2735